Skip to content

Exercise Training Improves Coronary Endothelial Dysfunction in Diabetes Mellitus Type 2 and Coronary Artery Disease

Long- But Not Short-term Exercise Training Improves Coronary Endothelial Dysfunction in Diabetes Mellitus Type 2 and Coronary Artery Disease

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00693537
Enrollment
Unknown
Registered
2008-06-09
Start date
Unknown
Completion date
Unknown
Last updated
2019-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease, Type 2 Diabetes Mellitus

Brief summary

Patients with type 2 diabetes mellitus suffer from accelerated coronary artery disease. We will assess the effects of exercise training on coronary endothelial function, vascular structure, and inflammation both in serum and skeletal muscle biopsies, as well as expression of diabetes candidate genes.

Interventions

BEHAVIORALExercise training

4 weeks in-hospital exercise training (6x15 min bicycle/day, 5 days/week) followed by a 5 months ambulatory exercise program (30 min ergometer/day, 5 days/week, plus 1h group exercise/week)

Sponsors

Paracelsus Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED

Eligibility

Sex/Gender
ALL
Age
50 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* written informed consent * preserved left ventricular function (left ventricular ejection fraction ≥ 50%) * a physical work capacity ≥ 50 W * at least one significant coronary stenosis \> 50%, whereas either the left anterior descending (LAD) or circumflex artery (RCX) has to be free from disease or stenoses ≤ 25% for the assessment of intracoronary flow measurements

Exclusion criteria

* diseases further affecting endothelial function * untreated hypertension (systolic blood pressure \> 160 mm Hg or a diastolic blood pressure of \> 90 mm Hg) * cigarette smoking during the previous six months * LDL-cholesterol \> 4.3 mmol/l * ventricular tachyarrhythmias * chronic obstructive pulmonary disease * severe renal or hepatic dysfunction * valvular heart disease * myocardial infarction within the previous 4 weeks

Countries

Austria

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026